Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02612311
Title Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors TG Therapeutics, Inc.
Indications

chronic lymphocytic leukemia

Therapies

Ublituximab

Chlorambucil + Obinutuzumab

Umbralisib

Age Groups: adult
Covered Countries USA | ITA | ESP


No variant requirements are available.